|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1997 (US)
|
|
gptkbp:approvedBy
|
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:ATCCode
|
N04BC04
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
Adartrel
Requip
|
|
gptkbp:CASNumber
|
91374-21-9
|
|
gptkbp:contraindication
|
hypersensitivity to ropinirole
|
|
gptkbp:developer
|
GlaxoSmithKline
|
|
gptkbp:drugClass
|
dopamine agonist
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
extended-release tablet
immediate-release tablet
|
|
gptkbp:hasMolecularFormula
|
C16H24N2O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ropinirole
|
|
gptkbp:interactsWith
|
ciprofloxacin
antipsychotics
estrogens
|
|
gptkbp:KEGGID
|
D08413
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor agonist
dopamine D3 receptor agonist
|
|
gptkbp:meltingPoint
|
250°C
|
|
gptkbp:metabolism
|
liver
inactive metabolites
|
|
gptkbp:notRecommendedFor
|
children
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:proteinBinding
|
40%
|
|
gptkbp:PubChem_CID
|
4897
5073
CHEMBL732
|
|
gptkbp:riskFactor
|
impulse control disorders
sleep attacks
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
nausea
dizziness
hallucinations
somnolence
|
|
gptkbp:synonym
|
2-(2-indolinyl)-N-propyl-N-ethylamine
|
|
gptkbp:UNII
|
M4I0D6VV5M
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:restless_legs_syndrome
|
|
gptkbp:bfsParent
|
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|